Media stories about Cesca Therapeutics (NASDAQ:KOOL) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cesca Therapeutics earned a news impact score of 0.07 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.6853785900783 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
NASDAQ:KOOL opened at $1.66 on Friday. The company has a current ratio of 2.06, a quick ratio of 1.23 and a debt-to-equity ratio of 0.16. Cesca Therapeutics has a 12-month low of $1.50 and a 12-month high of $6.44.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/cesca-therapeutics-kool-receives-media-sentiment-rating-of-0-07.html.
About Cesca Therapeutics
Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.